Landfar Bio-medicine Co., Ltd (SHE:000504)
China · Delayed Price · Currency is CNY 8.62
-0.04 (-0.46%)
Feb 13, 2026, 3:04 PM CST
Landfar Bio-medicine Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 125.28 | 134.26 | 136.44 | 194.48 | 156.54 | 175.43 |
Other Revenue | 0.19 | 0.19 | 0.35 | 5.86 | 0.08 | 0.13 |
| 125.47 | 134.45 | 136.79 | 200.35 | 156.62 | 175.56 | |
Revenue Growth (YoY) | 0.82% | -1.71% | -31.72% | 27.92% | -10.79% | 30.86% |
Cost of Revenue | 45.74 | 44.77 | 44.85 | 72.98 | 46.21 | 79.8 |
Gross Profit | 79.72 | 89.68 | 91.95 | 127.36 | 110.4 | 95.77 |
Selling, General & Admin | 74.46 | 82.37 | 89.66 | 112.91 | 105.39 | 67 |
Research & Development | 8.89 | 9.69 | 12.57 | 9.99 | 8.54 | 4.98 |
Other Operating Expenses | 1.67 | 0.66 | 0.23 | -6.41 | 1.3 | 1.17 |
Operating Expenses | 95.87 | 105.02 | 128.54 | 140.27 | 132.34 | 75.26 |
Operating Income | -16.14 | -15.34 | -36.59 | -12.91 | -21.94 | 20.51 |
Interest Expense | -0.87 | -1.46 | -11.07 | -12.9 | -15.96 | -4.01 |
Interest & Investment Income | 8.32 | 5.72 | 3.27 | 1.78 | 2.46 | 0.21 |
Currency Exchange Gain (Loss) | 0 | 0 | 0 | 0 | 0 | -0 |
Other Non Operating Income (Expenses) | -10.4 | -10.41 | -7.78 | 3.35 | -1 | -0.61 |
EBT Excluding Unusual Items | -19.1 | -21.5 | -52.17 | -20.68 | -36.43 | 16.1 |
Impairment of Goodwill | - | - | -6.46 | - | -2.79 | - |
Gain (Loss) on Sale of Investments | -0.08 | -0.01 | 0.03 | -0.06 | -0.31 | -0.3 |
Gain (Loss) on Sale of Assets | 0.55 | 0.16 | 11.9 | 0.08 | 0.03 | 1.89 |
Asset Writedown | 1.49 | -0.47 | -0.46 | -0.9 | 0 | - |
Other Unusual Items | 0.64 | 0.97 | 2.44 | - | 9.28 | 1.28 |
Pretax Income | -16.49 | -20.85 | -44.71 | -21.56 | -30.23 | 18.97 |
Income Tax Expense | 1.7 | 3.07 | 2.07 | 7.9 | 2.87 | 4.33 |
Earnings From Continuing Operations | -18.19 | -23.93 | -46.78 | -29.46 | -33.1 | 14.64 |
Minority Interest in Earnings | 11.99 | 4.08 | 18.61 | 17 | 13.98 | -6.48 |
Net Income | -6.2 | -19.85 | -28.17 | -12.46 | -19.13 | 8.15 |
Net Income to Common | -6.2 | -19.85 | -28.17 | -12.46 | -19.13 | 8.15 |
Net Income Growth | - | - | - | - | - | -56.64% |
Shares Outstanding (Basic) | 330 | 331 | 313 | 311 | 319 | 272 |
Shares Outstanding (Diluted) | 330 | 331 | 313 | 311 | 319 | 272 |
Shares Change (YoY) | -0.62% | 5.67% | 0.51% | -2.30% | 17.27% | -13.28% |
EPS (Basic) | -0.02 | -0.06 | -0.09 | -0.04 | -0.06 | 0.03 |
EPS (Diluted) | -0.02 | -0.06 | -0.09 | -0.04 | -0.06 | 0.03 |
EPS Growth | - | - | - | - | - | -50.00% |
Free Cash Flow | 12.18 | -13.47 | 30.36 | 149.44 | 75.14 | -211.69 |
Free Cash Flow Per Share | 0.04 | -0.04 | 0.10 | 0.48 | 0.24 | -0.78 |
Gross Margin | 63.54% | 66.70% | 67.22% | 63.57% | 70.49% | 54.55% |
Operating Margin | -12.87% | -11.41% | -26.75% | -6.44% | -14.01% | 11.68% |
Profit Margin | -4.94% | -14.76% | -20.59% | -6.22% | -12.21% | 4.64% |
Free Cash Flow Margin | 9.71% | -10.02% | 22.19% | 74.59% | 47.97% | -120.58% |
EBITDA | -14 | -12.81 | -33.54 | -9.98 | -18.41 | 23.86 |
EBITDA Margin | -11.16% | -9.53% | -24.52% | -4.98% | -11.76% | 13.59% |
D&A For EBITDA | 2.15 | 2.53 | 3.05 | 2.93 | 3.53 | 3.35 |
EBIT | -16.14 | -15.34 | -36.59 | -12.91 | -21.94 | 20.51 |
EBIT Margin | -12.87% | -11.41% | -26.75% | -6.44% | -14.01% | 11.68% |
Effective Tax Rate | - | - | - | - | - | 22.84% |
Revenue as Reported | 125.47 | 134.45 | 136.79 | 200.35 | 156.62 | 175.56 |
Advertising Expenses | - | 3.75 | 5.47 | 4.82 | 10.24 | 0.56 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.